Xinhua Pharmaceutical announced that in March 2025, the company submitted the registration application data for drug marketing license registration for the domestic production of dagliflozin tablets to the CDE and was accepted. The “Drug Registration Certificate” approved and issued by the State Drug Administration in August 2026. The review concluded that registration was approved. The specifications were 10 mg and 5 mg.

Xinhua Pharmaceutical announced that in March 2025, the company submitted the registration application data for drug marketing license registration for the domestic production of dagliflozin tablets to the CDE and was accepted. The “Drug Registration Certificate” approved and issued by the State Drug Administration in August 2026. The review concluded that registration was approved. The specifications were 10 mg and 5 mg.